Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.71 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.71 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.71 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.71 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.59 |
| ▸ | METAP1 | P53582 | 2/20 | 0.57 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063517 | 0.87 | S1PR1 (0.85) | S1PR1S1PR3S1PR2S1PR4ENPEP | |
| SCHEMBL5135218 | 0.85 | S1PR1 (0.96) | S1PR1S1PR3S1PR2S1PR4ENPEP | |
| SCHEMBL28381669 | 0.85 | S1PR2 (0.70) | S1PR1S1PR3S1PR2S1PR4ENPEP | |
| SCHEMBL5059525 | 0.84 | S1PR1 (0.62) | S1PR1S1PR3S1PR2S1PR4ENPEP | |
| SCHEMBL14338654 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4FDPS | |
| SCHEMBL14338673 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4FDPS | |
| SCHEMBL14338675 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4FDPS | |
| SCHEMBL14338651 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4FDPS | |
| SCHEMBL14338665 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4FDPS | |
| SCHEMBL5419041 | 0.84 | S1PR1 (1.00) | S1PR1S1PR3S1PR2S1PR4FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| EP-1077690-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | Neurochem, Inc. (CA) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | S1PR1 261/4885S1PR3 186/4885S1PR2 270/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | S1PR1 2186/4885S1PR3 1508/4885S1PR2 2283/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | S1PR1 2408/4885S1PR3 1651/4885S1PR2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.